Pacific Biosciences of California Inc
F:P09
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pacific Biosciences of California Inc
F:P09
|
US |
|
C
|
CrowdStrike Holdings Inc
LSE:0A3N
|
US |
|
P
|
Park National Corp
AMEX:PRK
|
US |
|
Bitmine Immersion Technologies Inc
OTC:BMNR
|
US |
|
Lu-Ve SpA
MIL:LUVE
|
IT |
|
Strike Co Ltd
TSE:6196
|
JP |
|
P
|
Porr AG
VSE:POS
|
AT |
|
Sprinklr Inc
NYSE:CXM
|
US |
|
Securitas AB
STO:SECU B
|
SE |
|
Embotelladora Andina SA
NYSE:AKO.A
|
CL |
|
T
|
Tiger Brands Ltd
JSE:TBS
|
ZA |
|
C
|
China South Publishing & Media Group Co Ltd
SSE:601098
|
CN |
|
AIA Group Ltd
LSE:0A6Q
|
HK |
|
S
|
Swire Pacific Ltd
SWB:SWI
|
HK |
|
L
|
Loews Corp
SWB:LTR
|
US |
|
G
|
Globrands Group Ltd
TASE:GLRS
|
IL |
|
Vince Holding Corp
NYSE:VNCE
|
US |
Pacific Biosciences of California Inc
Pacific Biosciences of California, or PacBio, makes DNA sequencing systems that let researchers read long stretches of genetic code. Its main products are sequencing instruments, the consumable chips and reagents used in those machines, and service and support agreements. The company’s technology is aimed at scientists who need highly detailed views of genomes, not consumer or hospital testing. PacBio sells mainly to academic research labs, biotechnology and pharmaceutical companies, government labs, and some clinical and applied testing groups. These customers use the systems for genome assembly, rare disease research, cancer research, plant and animal genetics, and other work where long DNA reads matter. PacBio makes money by placing instruments and then repeatedly selling the consumables that run on them, along with maintenance and support. What sets PacBio apart is its focus on long-read sequencing. Many sequencing tools read DNA in short pieces, but PacBio’s systems are designed to read longer sections, which helps customers detect structural changes, resolve complex regions of the genome, and build more complete genetic maps. That makes PacBio a specialist supplier in a research market where accuracy, depth, and the ability to see difficult parts of the genome are the main reasons to buy.
Pacific Biosciences of California, or PacBio, makes DNA sequencing systems that let researchers read long stretches of genetic code. Its main products are sequencing instruments, the consumable chips and reagents used in those machines, and service and support agreements. The company’s technology is aimed at scientists who need highly detailed views of genomes, not consumer or hospital testing.
PacBio sells mainly to academic research labs, biotechnology and pharmaceutical companies, government labs, and some clinical and applied testing groups. These customers use the systems for genome assembly, rare disease research, cancer research, plant and animal genetics, and other work where long DNA reads matter. PacBio makes money by placing instruments and then repeatedly selling the consumables that run on them, along with maintenance and support.
What sets PacBio apart is its focus on long-read sequencing. Many sequencing tools read DNA in short pieces, but PacBio’s systems are designed to read longer sections, which helps customers detect structural changes, resolve complex regions of the genome, and build more complete genetic maps. That makes PacBio a specialist supplier in a research market where accuracy, depth, and the ability to see difficult parts of the genome are the main reasons to buy.
Revenue: PacBio reported second-quarter revenue of $39 million, roughly flat year over year, with growth in consumables and a rebound in Revio demand partly offset by weaker Vega sales and continued funding pressure in the Americas.
Leadership: Christian Henry stepped down as CEO immediately, and Mark Van Oene took over as President and CEO. The company said the transition is seamless and that Van Oene will keep the focus on clinical growth and execution.
SPRQ-Nx: Full commercial rollout of SPRQ-Nx remains the key growth catalyst. Customer interest is strong, more than a third of the installed base opted into the enabling software in June, and management expects adoption to build through the second half.
Guidance cut: Management lowered full-year 2026 revenue guidance to $155 million to $165 million and cash flow breakeven timing moved out to 2028 from the prior expectation of the end of 2027.
Margins: Gross margin guidance was cut to 35% to 37% because of elevated compute and memory costs, temporary Vega manufacturing transition costs, and a slower SPRQ-Nx ramp than previously expected.
Clinical momentum: Clinical adoption is becoming a bigger part of the story, especially in EMEA, and management highlighted recent publications and new customer wins as evidence that HiFi sequencing is moving deeper into routine clinical use.
